Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors
October 6th, 2021
Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience
Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Krysalis VX Innovations Inc. (“Krysalis”), the Virtual experience (“VX”)-focused company designing the delivery of immersive, headset-free experiences through the KrysalisTM Pod system that will offer treatment options for cognitive, psychological, motor and functional impairments across various clinical health conditions, has appointed a distinguished and future-facing advisory team composed of Alex McDowell, Jon 9, Austin Blaisdell, and the three minds behind sonic engineering company, Resonant Devices, Kent Noonan, Erik Larson and Casey Atteberry.
Krysalis was formed pursuant to a joint venture agreement between Lobe and Virtual Psychedelics Incorporated (“VPI”) announced on April 27, 2021, where Krysalis is owned 50% by Lobe and 50% by VPI.
This advisory group will assist Krysalis through its first iteration of the KrysalisTM Pod. The current leadership team of Krysalis, CEO and social network-transmedia pioneer, Josh Shore; Hollywood director, futurist, and KrysalisTM Pod project lead, Brett Leonard; Professor and Director of Medical Virtual Reality at USC’s Institute for Creative Technologies, Dr. Albert (Skip) Rizzo; and VIP Event Producer, William (Billy) Alfonso (Formula-1, Cirque du Soleil) – are thrilled that the KrysalisTM Pod development will now benefit from representation and expertise of the advisory team that spans across arts, technology, design, academic and industry sectors.
“As a cinematic storyteller, having told cautionary tales of the transformative power of Virtual Reality in my movies, to now be involved in the actual reality of using this technology thanks to our groundbreaking partnership with Lobe Sciences and the incredible advisory group being announced here, is the realization of my greatest hopes for Virtual eXperience (VX) to be a positive force for healing the human spirit,” said Brett Leonard. “The best part is, with the development of the KrysalisTM Pod, no one in these therapeutic environments will have to strap an uncomfortable device on their head.”
Krysalis is committed to further developing systems that deliver virtual experience in tandem with psychedelics for research and clinical therapy, developing VR systems without psychedelics for recreational purposes such as gaming, and is focused on the development of the KrysalisTM Pod. The KrysalisTM Pod is new technology that will harness biometric feedback to make visible the tangible combined effects of virtual reality (“VR”) and psychedelics on biometric activity in real time. With this ability, the implementer (researcher or clinician) will be able to monitor both the psychedelic and the immersive experience such that it will be uniquely tailored to individual responses, and thus moderated to maximize the desired effect and therapeutic outcomes.
“I am impressed with the depth and capabilities of the Advisory team assembled by Krysalis management,” said Philip Young, CEO Lobe Sciences Ltd. “We have confidence that working together they will be able to create an industry leading VX experience that may aid those suffering from depression, PTSD and other mental health issues.”
This advisory team will be pivotal in defining aesthetic and pragmatic attributes of Krysalis VX’s treatment-oriented technology. The advisory team consists of:
Alex McDowell Award-winning designer, storyteller, and founder and creative director of Experimental Design where McDowell and his team design immersive story worlds for industries and institutions. He is simultaneously a professor of practice at USC School of Cinema, where he directs the World Building Media Lab and World Building Institute and teaches world building as a media and platform-agnostic narrative design practice. Alex is also known as one of the top Hollywood production designers, having worked on some of the biggest visionary Hollywood blockbusters such as Steven Spielberg’s “Minority Report”.
Jon 9 is a Creative Technologist who handles large-scale digital display projects, streaming immersive spaces, content creation and post-production management for complex systems. He’s realized massive projects including Cirque du Soleil: Beatles LOVE at The Mirage Las Vegas, installations with Disney, and many others with icons and mega-brands from Michael Jackson and Aretha Franklin to Audi and The Emmy Awards. His expertise is rooted in developing experiential media spaces that require new techniques and technologies.
Austin Blaisdell is a design strategist and art director who uses 3D printing, Virtual Reality, and the entire digital universe to project visions spanning all arts-related genres. His spatial design, visual direction, and design solutions may be experienced internationally, at exhibitions from Los Angeles to New York to Paris.
Kent Noonan is an Electronic Engineer whose expertise spans all areas of design and manufacturing, lasers and optics, high performance electronics and tough industrial devices, alternative healing with light and electromagnetic frequencies, free energy devices and alternate fuels, plasma, cymatics, and structured water research.
Erik Larson is an inventor, design engineer, musician, instrument builder, and entrepreneur. His professional specialties include business development, business management, patent and IP development, product development, technology integration, systems design, and team building.
Casey Atteberry is a mathematician striving to translate material in an approachable way to people of all ages and levels of interest. He has been an independent math and acoustical physics research scientist for nearly two decades, studying concepts from quantum computation to cymatics and fluid dynamics.
* * *
About Krysalis VX Innovations Inc.
Krysalis VX Innovations Inc. exists to design sophisticated, immersive treatments for psychological, cognitive and physical challenges. The KrysalisTM Pod will be designed to be powered by a custom tech stack incorporating advanced display technology and state-of-the-art bio-monitoring with the goal of improving psychedelic therapy by optimizing set, setting and the overall experience for clinical and other uses. The KrysalisTM Pod will deliver headset-free, virtual experiences that integrate multi-sensory stimulation to create an application that can offer treatment options for cognitive, psychological, motor and functional impairments across a wide range of clinical health conditions.
About Virtual Psychedelics Incorporated (“VPI”)
VPI was formed to pioneer the integration of Psychedelic Therapies with Virtual Experience known as “VX” (Virtual Reality, Augmented Reality & Mixed Reality). Founded by the leading minds in both clinical and entertainment-based Virtual Reality, VPI is dedicated to developing new approaches for the treatment of neurological and psychiatric conditions, and for promoting wellness, alongside the technologies and processes to make them scalable. In addition to medicinal applications, this marriage of ancient and modern technologies has enormous potential for promoting self-understanding and social transformation.
About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
For press inquiries on Krysalis, please contact Jessie Cohen PR & Consulting:
+1 415 623 0150
Lobe Sciences Ltd.
Philip J Young, CEO
Tel: (949) 505-5623
NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward-Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, statements related to the development and commercialization of the KrysalisTM Pod, including systems, treatments and benefits thereof, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices, including the KrysalisTM Pod, produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; Krysalis may be unsuccessful in designing and commercializing the KrysalisTM Pod and/or the risk that the Company may not realize a return on its investment in Krysalis; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.